10 results on '"Zhou, Dun-Hua"'
Search Results
2. Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study
- Author
-
Qiu, Kun-yin, Zhou, Dun-hua, Liao, Xiong-yu, Huang, Ke, Li, Yang, Xu, Hong-gui, Weng, Wen-jun, Xu, Lu-hong, and Fang, Jian-pei
- Published
- 2022
- Full Text
- View/download PDF
3. TARGET based m6A methylation-related genes predict prognosis relapsed B-cell acute lymphoblastic leukemia.
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, Fang, Jian-pei, and Zhou, Dun-hua
- Abstract
Purpose: The current study aims to investigate the significance of N6-methyladenosine (m
6 A) methylationrelated genes in the clinical prognosis of childhood relapsed B-cell acute lymphoblastic leukemia (B-ALLL) patient. Methods: Transcriptome data and corresponding clinical data on m6 A methylation-related genes (including 20 genes) were obtained from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) database. Results: The bone marrow (BM) samples of 134 newly diagnosed (naive) and 116 relapsed B-ALL from TARGET were enrolled in the current study. Three genes (FTO, HNRNPC, RBM15B) showed significant up-regulation in relapsed B-ALL compared with that in naive B-ALL.The three genes had a significantly worse survival (P < 0.05). The LASSO Cox regression model was used to select the most predictive genes as prognostic indicators, and YTHDC1 and FTO were identified as prognostic factors for relapsed B-ALL. Finally, the results of multivariate regression analysis showed that the risk score of m6 A methylation-related genes was an independent prognostic factor in relapsed B-ALL (P < 0.05). Conclusion: We found that the expression levels of m6 A methylation-related genes were different in naive and relapsed patients with B-ALL and correlated with survival and prognosis.This implies that m6 A methylation-related genes may be promising prognostic indicators or therapeutic targets for relapsed B-ALL. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, He, Zhan-wen, Wu, Ruo-hao, Li, Yang, Xu, Lu-hong, Zhou, Dun-hua, and Fang, Jian-pei
- Published
- 2021
- Full Text
- View/download PDF
5. Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol.
- Author
-
Wang, Jian, Jia, Wen-Guang, Yang, Li-Hua, Kuang, Wen-Yong, Huang, Li-Bin, Chen, Hui-Qin, Wang, Li-Na, Zhou, Dun-Hua, and Liao, Ning
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,DISEASE relapse ,PANCREATITIS - Abstract
Asparaginase-associated pancreatitis (AAP) is a common and fatal complication after ASNase treatment in acute lymphoblastic leukemia(ALL). Here, a total of 1063 pediatric ALL patients treated with SCCLG-ALL-2016 regimen were collected since October 2016 to June 2020, including 35 patients with AAP. The clinical characteristics of AAP and non-AAP patients were compared. In AAP patients, the possible factors that affected the recurrence of AAP were analyzed, and the possible risk factors related to ALL-relapse were discussed. The results showed that age was a risk factor (P =.017) that affect the occurrence of AAP. In AAP patients, AAP tended to develop after the second use of PEG-ASNase (25.71%). In the follow-up chemotherapy, 17 patients re-exposed to ASNase and 7 cases developed AAP again with a percentage was 41.2%. There were no special factors that related with the recurrence of AAP. This study also found no association between the occurrence of AAP and prognosis of ALL, with the 4-year incidence of ALL relapse in AAP and non-AAP patients were 15.9% v.s.11.7% (HR: 1.009, 95% CI:0.370–2.752, P =.986), and there were no special factors that related with the ALL relapse among AAP patients. Based on the above results, the occurrence of AAP is related to age and should be vigilant after the second use of PEG-ASNase after use in pediatric ALL patients. Moreover, AAP is not associated with ALL relapse, but there is a high AAP recurrence rate when re-exposure to ASNase. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Analysis of clinical characteristics and prognostic factors associated with EBV-associated HLH in children.
- Author
-
Qiu, Kun-yin, Guo, Shu-yi, Zeng, Yang-hui, Liao, Xiong-yu, Lin, Shao-fen, Fang, Jian-pei, and Zhou, Dun-hua
- Subjects
PROGNOSIS ,HEMOPHAGOCYTIC lymphohistiocytosis ,CHILD mortality ,UNIVARIATE analysis ,STATISTICAL correlation - Abstract
Purpose Our aim is to analyze the clinical characteristics and prognostic factors of Epstein-Barr (EB) virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in children. Methods Children with newly diagnosed HLH were retrospectively analyzed. Results Finally, a total of 95 children with HLH were enrolled in this study, including 43 (45.3%) with EBV-HLH and 52 (54.7%) with non-EBV-HLH. Laboratory tests showed that the levels of absolute neutrophil count (ANC) decrease (P = 0.031) and triglycerides (TG) increase (P = 0.036) in the EBV-HLH group were statistically significant compared with those in the non-EBV-HLH group, respectively. We found that the remission rate during induction period in the EBV-HLH group and non-EBV-HLH group was 75.8% and 89.3%, respectively. The correlation analysis showed that the elevated degree of total bilirubin (TBIL) (P = 0.042), triglyceride (TG) (P = 0.009), serum ferritin (SF) (P = 0.008) and interleukin-8 (IL-8) (P = 0.004) were related with the remission rate during induction in the EBV-HLH group. Further univariate analysis showed that the elevated degree of TBIL (P = 0.048) and TG (P = 0.019) were significant risk factors for the remission rate during induction in the EBV-HLH group. In the multivariate analysis, we observed that there was statistical significance for the degree of TG elevation (P = 0.015) between the two groups. The correlation analysis showed that the elevated degree of TBIL (P = 0.030), the elevated degree of SF (P = 0.020) and the elevated degree of interleukin-6 (P = 0.010) were related to the induction mortality of children with EBV-HLH. Conclusion TBIL and TG are valid indicators to assess the efficacy and prognosis of EVBHLH among children in induction period. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.
- Author
-
Liao, Xiong‐yu, Fang, Jian‐pei, Zhou, Dun‐hua, and Qiu, Kun‐yin
- Subjects
ACUTE myeloid leukemia ,PROGNOSIS ,STEM cell transplantation ,CHILD patients ,OVERALL survival - Abstract
To evaluate the outcome and prognostic significance of CEBPA mutations among pediatric acute myeloid leukemia (AML) from TARGET dataset. A total of 1803 pediatric patients who were diagnosed with AML were classified into two groups based on the CEBPA status by using a retrospective cohort study method from September 1996 to December 2016. The incidence of CEBPA mutations was 18%. CEBPA mutations were significantly associated with elder age (p < 0.001), higher WBC (p = 0.004), higher proportion of peripheral blood blast (p < 0.001), normal karyotype (p < 0.001), low risk (p < 0.001) and higher complete remission induction rates (p < 0.05). Overall, CEBPA mutations patients had a significantly better 5‐year EFS (p < 0.001) and OS (p < 0.001) compared to CEBPA wild‐type patients, and this favorable impact was maintained even in the presence of FLT3/ITD mutations. Stem cell transplantation had no significant impact on the survival of patients with coexistence of CEBPA and FLT3/ITD mutations. Multivariate analysis demonstrated that mutated CEBPA were an independent favorable indicators of better outcome in terms of EFS (p = 0.007) and OS (p = 0.039). Our study demonstrate mutated CEBPA have an excellent outcome in pediatric AML patients. Furthermore, pediatric AML patients with coexistence of CEBPA and FLT3/ITD mutation appear to have favorable prognoses and might not required stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Eltrombopag as first‐line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation.
- Author
-
Qiu, Kun‐yin, Liao, Xiong‐yu, Huang, Ke, Wu, Ruo‐hao, Xu, Hong‐gui, Xu, Lu‐hong, Li, Yang, Weng, Wen‐jun, Zhou, Dun‐hua, and Fang, Jian‐pei
- Subjects
STEM cell transplantation ,CHILD patients ,PLATELET count ,ELTROMBOPAG ,DRUG efficacy ,THROMBOCYTOPENIA ,MULTIPLE regression analysis - Abstract
Aims: The purpose of this study is to examine the safety and efficacy of eltrombopag as first‐line treatment for thrombocytopenia among paediatric patients after haematopoietic stem cell transplantation (HSCT). Methods: Forty‐three childhood patients with thrombocytopenia after HSCT who received eltrombopag were retrospectively analysed. Result: Eltrombopag was began at the median of 27 days after HSCT and lasted for 24 days. Thirty‐five children responded to eltrombopag therapy, and the cumulative platelet recovery rate was 88.9%. The cumulative incidence of platelet recovery was lower (83.9 vs 100%; P =.035) in patients with decreased numbers of megakaryocytes before starting eltrombopag than in those with normal. Factors associated with a significantly elevated response to eltrobopag from univariate analysis were donor type. Results from the multiple regression analysis found that weight (hazard ratio [HR] = 0.7, 95% confidence interval [CI] 0.5–0.9, P =.022), platelet engraftment time (HR = 1.0, 95%CI 1.0–1.0, P =.012) and bone marrow megakaryocytes (HR = 8.0, 95%CI 1.5–43.3, P =.016) before starting eltrombopag were the independent risk factors. Based on Youden's index algorithm in the receiver‐operating characteristic curve, the optimal cut‐off value of the maintenance dose of eltrombopag in predicting nonresponders was 4 mg/kg. The area under the receiver‐operating characteristic curve was 0.923 with sensitivity of 97.8%, specificity of 87.9%, positive predictive value of 72.3%, and negative predictive value of 92%. None of the paediatric patients stopped using eltrombopag due to side effect or intolerability. Conclusion: Eltrombopag is effective and safe in paediatric patients with thrombocytopenia after HSCT. The number of megakaryocytes in bone marrow before eltrombopag treatment may serve as a predictor of the response to eltrombopag. We recommend that the maintenance dose of eltrombopag should not exceed 4 mg/kg/d. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. The early diagnostic value of serum galactomannan antigen test combined with chest computed tomography for invasive pulmonary aspergillosis in pediatric patients after hematopoietic stem cell transplantation.
- Author
-
Qiu, Kun‐yin, Liao, Xiong‐yu, Huang, Ke, Xu, Hong‐gui, Li, Yang, Fang, Jian‐pei, and Zhou, Dun‐hua
- Subjects
PULMONARY aspergillosis ,HEMATOPOIETIC stem cell transplantation ,TOMOGRAPHY ,FEBRILE neutropenia - Abstract
Objective: The purpose of our study was to evaluate the diagnostic value of serum galactomannan antigen (GM) testing combined with chest computed tomography (CT) of invasive pulmonary aspergillosis (IPA) in pediatric patients after hematopoietic stem cell transplantation. Methods: A retrospective nested case‐control study was conducted in the identifying IPA among pediatric patients. Results: A total of 141 eligible pediatric recipients with febrile neutropenia were enrolled in this study. All patients in the cases were diagnosed with proven‐probable IPA(PP‐IPA), while only 9 patients in the controls. GM testing was positive in 38 pediatric recipients in the cases and nine recipients in the controls with sensitivity of 62.3%, specificity of 81.8%. Among all patients with IPA, 46 patients in the cases and 9 patients in the controls had typical features of CT imaging with sensitivity of 79.3%, specificity of 85.2%. For discrimination of participants' GM testing combined with CT evaluation, the AUC of the diagnostic model was 0.887 with PPV of 0.764, and NPV of 0.872. Sensitivity was 0.793, and specificity was 0.852 in IPA. Conclusion: The combination methods with serum GM and CT scan might be used as a valuable marker for early diagnosis of IPA in pediatric patients after HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
- Author
-
Qiu, Kun‐yin, Liao, Xiong‐yu, Fang, Jian‐pei, Xu, Hong‐gui, Li, Yang, Huang, Ke, and Zhou, Dun‐hua
- Subjects
HEMATOPOIETIC stem cell transplantation ,MYCOSES ,THERAPEUTICS ,DRUG side effects ,POOR children - Abstract
Background: Invasive fungal disease (IFD) has a poor prognosis in children with hematological disorders after hematopoietic stem cell transplantation (HSCT). We assessed if drug combinations with different targets may improve the outcome. Methods: Retrospective study to assess the outcome of combination antifungal therapy (CAT) for proven‐probable IFD (PP‐IFD) in children with hematological disorders after HSCT from January 2008 to June 2018. Results: Over the 10‐year period, 95 PP‐IFD were diagnosed in pediatric recipients, median age of 5.6 years. Twenty‐seven patients received combinations of caspofungin and voriconazole, 28 patients received combinations of caspofungin and amphotericin B, and 40 patients received combinations of voriconazole and amphotericin B. The overall response rate of PP‐IFD was 77.9%, while the 100‐day overall survival rates were 66.8%. Univariate analysis showed that factors that significantly affected the response to combination treatments were type of combination (P = 0.02), the stem cell source (P = 0.04), the donor type (P = 0.03), HLA‐match (P = 0.03), aGVHD (P = 0.02), period of treatment (P = 0.044), use of corticosteroids (0.036), CD4:CD8 ratio (P = 0.014), and CMV viremia (P = 0.033). In addition, multivariate analysis demonstrated that only the type of combination remained a significant factor (odds ratio = 0.335, 95% confidence interval: 0.071‐0.812, P = 0.042). Forty‐three children suffered from mild and reversible adverse reactions, no serious side effects during treatment. Conclusion: A variety of factors can affect the outcome of CAT. Combination of caspofungin with voriconazole is a safe and helpful treatment option for HSCT recipients with IFD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.